摘要
目的探讨老年髓系随性白血病患者的不同治疗方式及其疗效。方法于2018年1月开展为期1年的研究,并在研究期间随机选取我院住院治疗的白血病患者作为案例探究最佳疗法。所有患者均被确诊为髓系白血病,在确诊同时将患者纳入试验组与常规组。常规组单纯应用CAG治疗方案(阿糖胞苷+阿克拉霉素+粒细胞集落刺激因子),试验组采用地西他滨结合CAG的治疗方案。以康复效果、不良反应以及生存质量等进行对比研究。结果试验组疗效显著优于常规组,P<0.05;试验组不良反应发生率明显少于常规组,P<0.05;干预之前两组患者的免疫指标无明显差异,数据之间的对比无意义,P>0.05;不同方案治疗后试验组免疫指标明显高于常规组,患者免疫指标改善效果突出,适用于统计学标准,P<0.05;试验组患者的平均生存率、疾病与事件相关生存期的数据均显著优于常规组,数据之间的差异较大且有意义,P<0.05。结论为髓系白血病患者提供CAG、地西他滨的结合方案具备显著干预效果,可以有效改善患者的临床症状并延长患者生存时间、提升生存质量,值得推广普及。
Objective To explore the different treatment methods and curative effects of elderly patients with myelogenous leukemia.Methods A one-year study was carried out in January 2018.During the study,the leukemia patients in our hospital were randomly selected as cases to explore the best treatment.All the patients were diagnosed as myeloid leukemia.At the same time,the patients were included into the experimental group and the conventional group.The conventional group was treated with CAG alone,and the experimental group was treated with dessicabine combined with CAG.The effects of rehabilitation,adverse reactions and quality of life were compared.Results The curative effect of the experimental group was significantly better than that of the conventional group(P Standard,P<0.05);The average survival rate,disease and event-related survival data of the experimental group were significantly better than those of the conventional group,and the difference between the data was significant,P<0.05.Conclusion The combination of CAG and dessicabine for patients with myeloid leukemia has a significant intervention effect,which can effectively improve the clinical symptoms,prolong the survival time and improve the quality of life of patients.It is worth popularizing.
作者
徐芝龙
陈以娜
吴梅
杜凤
马艳艳
XU Zhilong;CHEN Yina;WU Mei;DU Feng;MA Yanyan(Department of Hematology,People′s Hospital of Lanling County,Linyi 277700,China)
出处
《药学研究》
CAS
2020年第8期491-493,496,共4页
Journal of Pharmaceutical Research
